These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24690265)

  • 1. A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway.
    Nishimura Y; Takeda K; Ezawa R; Ishii J; Ogino C; Kondo A
    J Nanobiotechnology; 2014 Apr; 12():11. PubMed ID: 24690265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular trafficking of bio-nanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein.
    Somiya M; Sasaki Y; Matsuzaki T; Liu Q; Iijima M; Yoshimoto N; Niimi T; Maturana AD; Kuroda S
    J Control Release; 2015 Aug; 212():10-8. PubMed ID: 26074149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsule.
    Liu Q; Somiya M; Kuroda S
    World J Gastroenterol; 2016 Oct; 22(38):8489-8496. PubMed ID: 27784961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system.
    Kakudo T; Chaki S; Futaki S; Nakase I; Akaji K; Kawakami T; Maruyama K; Kamiya H; Harashima H
    Biochemistry; 2004 May; 43(19):5618-28. PubMed ID: 15134436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of hepatitis B virus pre-S1 (9-24) fusogenic peptide.
    Liu Q; Somiya M; Shimada N; Sakamoto W; Yoshimoto N; Iijima M; Tatematsu K; Nakai T; Okajima T; Maruyama A; Kuroda S
    Biochem Biophys Res Commun; 2016 May; 474(2):406-412. PubMed ID: 27120459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
    Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells.
    Yamada M; Oeda A; Jung J; Iijima M; Yoshimoto N; Niimi T; Jeong SY; Choi EK; Tanizawa K; Kuroda S
    J Control Release; 2012 Jun; 160(2):322-9. PubMed ID: 22100387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bio-nanocapsules displaying various immunoglobulins as an active targeting-based drug delivery system.
    Tatematsu K; Iijima M; Yoshimoto N; Nakai T; Okajima T; Kuroda S
    Acta Biomater; 2016 Apr; 35():238-47. PubMed ID: 26876802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clustered versus Uniform Display of GALA-Peptides on Carrier Nanoparticles: Enhancing the Permeation of Noncharged Fluid Lipid Membranes.
    Locke T; Sofou S
    Langmuir; 2017 Nov; 33(47):13625-13633. PubMed ID: 29096061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex carriers of affibody-displaying bio-nanocapsules and composition-varied liposomes for HER2-expressing breast cancer cell-specific protein delivery.
    Nishimura Y; Ishii J; Okazaki F; Ogino C; Kondo A
    J Drug Target; 2012 Dec; 20(10):897-905. PubMed ID: 23020553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytosolic targeting of macromolecules using a pH-dependent fusogenic peptide in combination with cationic liposomes.
    Kobayashi S; Nakase I; Kawabata N; Yu HH; Pujals S; Imanishi M; Giralt E; Futaki S
    Bioconjug Chem; 2009 May; 20(5):953-9. PubMed ID: 19388672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a macrophage-targeting and phagocytosis-inducing bio-nanocapsule-based nanocarrier for drug delivery.
    Li H; Tatematsu K; Somiya M; Iijima M; Kuroda S
    Acta Biomater; 2018 Jun; 73():412-423. PubMed ID: 29673839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes.
    Nishimura Y; Mieda H; Ishii J; Ogino C; Fujiwara T; Kondo A
    J Nanobiotechnology; 2013 Jun; 11():19. PubMed ID: 23800313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affibody-displaying bio-nanocapsules effective in EGFR, typical biomarker, expressed in various cancer cells.
    Nishimura Y; Ezawa R; Ishii J; Ogino C; Kondo A
    Bioorg Med Chem Lett; 2017 Jan; 27(2):336-341. PubMed ID: 27908760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives.
    Sasaki K; Kogure K; Chaki S; Nakamura Y; Moriguchi R; Hamada H; Danev R; Nagayama K; Futaki S; Harashima H
    Anal Bioanal Chem; 2008 Aug; 391(8):2717-27. PubMed ID: 18351325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Class I Tumor Antigen Presentation via Cytosolic Delivery of Exosomal Cargos by Tumor-Cell-Derived Exosomes Displaying a pH-Sensitive Fusogenic Peptide.
    Morishita M; Takahashi Y; Nishikawa M; Ariizumi R; Takakura Y
    Mol Pharm; 2017 Nov; 14(11):4079-4086. PubMed ID: 28977747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bio-nanocapsules for in vivo pinpoint drug delivery].
    Jung J; Kasuya T; Tanizawa K; Kuroda S
    Yakugaku Zasshi; 2007 May; 127(5):797-805. PubMed ID: 17473521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a fusiogenic peptide GALA for intracellular delivery.
    Nakase I; Kogure K; Harashima H; Futaki S
    Methods Mol Biol; 2011; 683():525-33. PubMed ID: 21053154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells.
    Matsuo H; Somiya M; Iijima M; Arakawa T; Kuroda S
    J Nanobiotechnology; 2018 Aug; 16(1):59. PubMed ID: 30077180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.
    Matsuo H; Yoshimoto N; Iijima M; Niimi T; Jung J; Jeong SY; Choi EK; Sewaki T; Arakawa T; Kuroda S
    Int J Nanomedicine; 2012; 7():3341-50. PubMed ID: 22848163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.